Our key revenue driver is CRINONE® (progesterone gel), a vaginal progesterone gel utilizing our sustained-release bioadhesive technology. CRINONE 8% was approved by the FDA in May 1997, and is indicated for progesterone supplementation or replacement as part of an Assisted Reproductive Technology (ART) treatment for infertile women with a progesterone deficiency.
Today CRINONE 8% has a strong and growing global presence. It is marketed in the U.S. by Actavis, Inc., and in over 60 countries around the world by Merck Serono, including most major markets.
For more information on CRINONE 8%, please visit Actavis' product website www.crinoneusa.com. For CRINONE patient support, or to report an adverse event, please contact Actavis as follows:
CRINONE® is a registered trademark of Actavis, Inc. in the U.S. and of Merck Serono S.A. outside the U.S.